WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

WuXi XDC Cayman Inc

WuXi XDC is a leading CRDMO focused on the global ADC and broader bioconjugate market and is dedicated to providing integrated services from concept development to commercialization. All services are provided from proximately located, state-of-the-art laboratories and manufacturing facilities, providing high efficiency and significant reduction of development timeline and costs. Our community of over 1000 skilled employees work across a global network to provide an open-access platform with the most comprehensive capabilities and technologies.  WuXi XDC enables its biopharmaceutical partners to innovate, accelerate, and transform the development of the bioconjugate industry, to the benefit of patients worldwide.

2268

COM:WUXIXDC

WuxiXDC

Last Close

26.00

22/11 03:59

Market Cap

19.17B

Beta: -

Volume Today

852K

Avg: -